靶向敲低腺苷转运体1通过降低炎症反应对阿尔茨海默病的保护作用研究

张效源; 马子腾; 贾云芳; 贺桂琼

doi:10.16016/j.2097-0927.202403052

您当前的位置：

首页 >

文章列表页 >

靶向敲低腺苷转运体1通过降低炎症反应对阿尔茨海默病的保护作用研究

基础医学 | 更新时间：2026-01-09

- 靶向敲低腺苷转运体1通过降低炎症反应对阿尔茨海默病的保护作用研究
- Knockdown of equilibrative nucleotide transporter 1 protects against Alzheimer's disease by reducing inflammatory response
- 陆军军医大学学报 2024年46卷第23期页码：2588-2598
- 作者机构：
  
  1.400016 重庆，重庆医科大学：神经科学研究中心
  2.400016 重庆，重庆医科大学：基础医学院生理教研室
  3.400016 重庆，重庆医科大学：基础医学院解剖教研室
- 作者简介：
  
  [ 贺桂琼，E-mail: guiqionghe@cqmu.edu.cnHE Guiqiong, E-mail: guiqionghe@cqmu.edu.cn
- 基金信息：
  
  重庆市教育委员会科学技术研究青年项目(KJQN202200454)
- DOI：10.16016/j.2097-0927.202403052
  中图分类号： R394-33;R394.3;R745.7
- 收稿：2024-03-12，
  
  修回：2024-04-19，
  
  纸质出版：2024-12-15
- 稿件说明：
移动端阅览
张效源, 马子腾, 贾云芳, 等. 靶向敲低腺苷转运体1通过降低炎症反应对阿尔茨海默病的保护作用研究[J]. 陆军军医大学学报, 2024,46(23):2588-2598.

Xiaoyuan ZHANG, Ziteng MA, Yunfang JIA, et al. Knockdown of equilibrative nucleotide transporter 1 protects against Alzheimer's disease by reducing inflammatory response[J]. Journal of Army Medical University, 2024, 46(23): 2588-2598.
张效源, 马子腾, 贾云芳, 等. 靶向敲低腺苷转运体1通过降低炎症反应对阿尔茨海默病的保护作用研究[J]. 陆军军医大学学报, 2024,46(23):2588-2598. DOI： 10.16016/j.2097-0927.202403052.

Xiaoyuan ZHANG, Ziteng MA, Yunfang JIA, et al. Knockdown of equilibrative nucleotide transporter 1 protects against Alzheimer's disease by reducing inflammatory response[J]. Journal of Army Medical University, 2024, 46(23): 2588-2598. DOI： 10.16016/j.2097-0927.202403052.

摘要

目的

通过构建腺苷转运体1(equilibrative nucleotide transporter 1，ENT1)过表达和敲低质粒，观察ENT1对阿尔茨海默病(Alzheimer’s disease，AD)的影响及可能的机制。

方法

利用分子克隆的方式构建ENT1过表达质粒pAAV-ENT1-mCherry和敲低质粒pAAV-ENT1shRNA-ZsGreen。将过表达质粒转染入小鼠神经元N2A细胞，将敲低质粒转染入含瑞士家族人APP695的N2A细胞(N2A-APP)。结合real-time qPCR和Western blot分别检测ENT1 mRNA和蛋白表达及炎症因子的变化，通过CCK-8试剂盒检测对细胞活性的影响。

结果

测序和real-time qPCR验证结果显示小鼠ENT1过表达和敲低质粒已成功构建。CCK-8检测结果显示，过表达ENT1水平24 h内细胞存活率显著下调(

0.05)，而当敲低ENT1时细胞存活率显著上调(

0.01)。Real-time qPCR检测进一步发现，ENT1过表达可引起细胞内炎症因子IL-1β、TNF-α、C1q-a和C1q-b水平的显著上调(

0.05)，而敲低ENT1时可逆转N2A-APP细胞内炎症因子水平的上调(

0.05)。

结论

靶向敲低ENT1的蛋白水平可通过降低炎症反应从而减轻AD的病理改变，ENT1可能是AD病理机制的一个潜在靶点。

Abstract

Objective

To study the role and mechanisms of equilibrative nucleotide transporter 1 (ENT1) on Alzheimer's disease (AD) by constructing ENT1 overexpression and knockdown plasmids.

Methods

Molecular cloning was used to construct the ENT1 overexpression (pAAV-ENT1-mCherry) and knockdown (pAAV-ENT1shRNA-ZsGreen) plasmids. The overexpression plasmids and the knockdown plasmids were transfected into N2A cells (mouse Neuro A2 cells) and N2A-APP cells (N2A cells stably expressing human APP695). The expression of ENT1 and inflammatory factors at mRNA and protein levels were detected by real-time qPCR and Western blotting

respectively

and the change in cell viability were measured with CCK-8 assay.

Results

Sequencing and real-time qPCR indicated that ENT1 overexpression and knockdown plasmids were successfully constructed. CCK-8 assay showed that ENT1 overexpression significantly reduced the cell survival rate within 24 h (

0.05)

while its knockdown increased the cell survival rate (

0.01). Real-time qPCR displayed that overexpression of ENT1 enhanced the expression levels of inflammatory factors

such as IL-1β

TNF-α

C1q-a and C1q-b in N2A cells (

0.05)

while ENT1 knockdown reversed the above changes in inflammatory factors in N2A-APP cells (

0.05).

Conclusion

Knockdown of ENT1 attenuates pathological changes in AD by reducing the inflammatory response. ENT1 may be a potential target in the pathological mechanism of AD.

关键词

Keywords

references

LANE C A, HARDY J, SCHOTT J M. Alzheimer's disease[J]. Eur J Neurol, 2018, 25(1): 59-70. DOI: 10.1111/ene.13439.

CASTELLANI R J, ROLSTON R K, SMITH M A. Alzheimer disease[J]. Dis Mon, 2010, 56(9): 484-546. DOI: 10.1016/j.disamonth.2010.06.001.

PROVIAS J, JEYNES B. The role of the blood-brain barrier in the pathogenesis of senile plaques in Alzheimer's disease[J]. Int J Alzheimers Dis, 2014, 2014: 191863. DOI: 10.1155/2014/191863.

CHANG C P, WU K C, LIN C Y, et al . Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases[J ] . J Biomed Sci, 2021, 28(1): 70. DOI: 10.1186/s12929-021-00766-y.

ANTONIOLI L, CSÓKA B, FORNAI M, et al . Adenosine and inflammation: what's new on the horizon?[J ] . Drug Discov Today, 2014, 19(8): 1051-1068. DOI: 10.1016/j.drudis.2014.02.010.

DIAS R B, ROMBO D M, RIBEIRO J A, et al . Adenosine: setting the stage for plasticity[J ] . Trends Neurosci, 2013, 36(4): 248-257. DOI: 10.1016/j.tins.2012.12.003.

WILLIAMS-KARNESKY R L, SANDAU U S, LUSARDI T A, et al . Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis[J ] . J Clin Invest, 2013, 123(8): 3552-3563. DOI: 10.1172/JCI65636.

CUNHA R A. How does adenosine control neuronal dysfunction and neurodegeneration?[J]. J Neurochem, 2016, 139(6): 1019-1055. DOI: 10.1111/jnc.13724.

PORKKA-HEISKANEN T, KALINCHUK A V. Adenosine, energy metabolism and sleep homeostasis[J]. Sleep Med Rev, 2011, 15(2): 123-135. DOI: 10.1016/j.smrv.2010.06.005.

LI B, GU L, HERTZ L, et al . Expression of nucleoside transporter in freshly isolated neurons and astrocytes from mouse brain[J ] . Neurochem Res, 2013, 38(11): 2351-2358. DOI: 10.1007/s11064-013-1146-5.

OLIVEROS A, STARSKI P, LINDBERG D, et al . Label-free neuroproteomics of the hippocampal-accumbal circuit reveals deficits in neurotransmitter and neuropeptide signaling in mice lacking ethanol-sensitive adenosine transporter[J ] . J Proteome Res, 2017, 16(4): 1445-1459. DOI: 10.1021/acs.jproteome.6b00830.

杜烨湘, 罗敏, 冯敏, 等. 甘草素通过抗炎发挥对阿尔茨海默病的保护作用[J]. 免疫学杂志, 2019, 35(4): 327-333. DOI: 10.13431/j.cnki.immunol.j.20190051.

DU Y X, LUO M, FENG M, et al . The protective effect of liquiritigenin on Alzheimer's disease by inhibiting inflammation response[J ] . Immunol J, 2019, 35(4): 327-333. DOI: 10.13431/j.cnki.immunol.j.20190051.

JIA L F, QUAN M N, FU Y, et al . Dementia in China: epidemiology, clinical management, and research advances[J ] . Lancet Neurol, 2020, 19(1): 81-92. DOI: 10.1016/S1474-4422(19)30290-X.

TIWARI S, ATLURI V, KAUSHIK A, et al . Alzheimer's disease: pathogenesis, diagnostics, and therapeutics[J ] . Int J Nanomedicine, 2019, 14: 5541-5554. DOI: 10.2147/IJN.S200490.

ALONSO-ANDRÉS P, ALBASANZ J L, FERRER I, et al . Purine-related metabolites and their converting enzymes are altered in frontal, parietal and temporal cortex at early stages of Alzheimer's disease pathology[J ] . Brain Pathol, 2018, 28(6): 933-946. DOI: 10.1111/bpa.12592.

CHOI J S, BERDIS A J. Nucleoside transporters: biological insights and therapeutic applications[J]. Future Med Chem, 2012, 4(11): 1461-1478. DOI: 10.4155/fmc.12.79.

YOUNG J D, YAO S Y, BALDWIN J M, et al . The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29[J ] . Mol Aspects Med, 2013, 34(2/3): 529-547. DOI: 10.1016/j.mam.2012.05.007.

BOSWELL-CASTEEL R C, HAYS F A. Equilibrative nucleoside transporters-a review[J]. Nucleosides Nucleotides Nucleic Acids, 2017, 36(1): 7-30. DOI: 10.1080/15257770.2016.1210805.

HSU C L, LIN W Y, SESHASAYEE D, et al . Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis[J ] . Science, 2012, 335(6064): 89-92. DOI: 10.1126/science.1213682.

DARMANIS S, SLOAN S A, ZHANG Y, et al . A survey of human brain transcriptome diversity at the single cell level[J ] . Proc Natl Acad Sci U S A, 2015, 112(23): 7285-7290. DOI: 10.1073/pnas.1507125112.

CHANG C P, CHANG Y G, CHUANG P Y, et al . Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy[J ] . Acta Neuropathol Commun, 2021, 9(1): 112. DOI: 10.1186/s40478-021-01213-7.

KIM T, RAMESH V, DWORAK M, et al . Disrupted sleep-wake regulation in type 1 equilibrative nucleoside transporter knockout mice[J ] . Neuroscience, 2015, 303: 211-219. DOI: 10.1016/j.neuroscience.2015.06.037.

BAO K T, LI Y Y, WEI J L, et al . Fangchinoline suppresses conjunctival melanoma by directly binding FUBP2 and inhibiting the homologous recombination pathway[J ] . Cell Death Dis, 2021, 12(4): 380. DOI: 10.1038/s41419-021-03653-4.

JAGUST W. Imaging the evolution and pathophysiology of Alzheimer disease[J]. Nat Rev Neurosci, 2018, 19(11): 687-700. DOI: 10.1038/s41583-018-0067-3.

FAKHOURY M. Inflammation in Alzheimer's disease[J]. Curr Alzheimer Res, 2020, 17(11): 959-961. DOI: 10.2174/156720501711210101110513.

LIAO H F, YE J, GAO L L, et al . The main bioactive compounds of Scutellaria baicalensis Georgi. for alleviation of inflammatory cytokines: a comprehensive review[J ] . Biomed Pharmacother, 2021, 133: 110917. DOI: 10.1016/j.biopha.2020.110917..

NEWCOMBE E A, CAMATS-PERNA J, SILVA M L, et al . Inflammation: the link between comorbidities, genetics, and Alzheimer's disease[J ] . J Neuroinflammation, 2018, 15(1): 276. DOI: 10.1186/s12974-018-1313-3.

BREDER C D, TSUJIMOTO M, TERANO Y, et al . Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system[J ] . J Comp Neurol, 1993, 337(4): 543-567. DOI: 10.1002/cne.903370403.

DAVIS S, LAROCHE S. What can rodent models tell us about cognitive decline in Alzheimer's disease?[J]. Mol Neurobiol, 2003, 27(3): 249-276. DOI: 10.1385/MN:27:3:249.

WU D M, LIU J P, LIU J, el al . Immune pathway activation in neurons triggers neural damage after stroke[J ] . Cell Report, 2023, 42(11): 113368. DOI: 10.1016/j.celrep.2023.113368.

LULL M E, BLOCK M L. Microglial activation and chronic neurodegeneration[J]. Neurotherapeutics, 2010, 7(4): 354-365. DOI: 10.1016/j.nurt.2010.05.014.

NOVOA C, SALAZAR P, CISTERNAS P, et al . Inflammation context in Alzheimer's disease, a relationship intricate to define[J ] . Biol Res, 2022, 55(1): 39. DOI: 10.1186/s40659-022-00404-3.

THAKUR S, DHAPOLA R, SARMA P, et al . Neuroinflammation in Alzheimer's disease: current progress in molecular signaling and therapeutics[J ] . Inflammation, 2023, 46(1): 1-17. DOI: 10.1007/s10753-022-01721-1.

RICKLIN D, HAJISHENGALLIS G, YANG K, et al . Complement: a key system for immune surveillance and homeostasis[J ] . Nat Immunol, 2010, 11(9): 785-797. DOI: 10.1038/ni.1923.

TENNER A J, STEVENS B, WOODRUFF T M. New tricks for an ancient system: physiological and pathological roles of complement in the CNS[J]. Mol Immunol, 2018, 102: 3-13. DOI: 10.1016/j.molimm.2018.06.264.

SHARP T H, BOYLE A L, DIEBOLDER C A, et al . Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b[J ] . Proc Natl Acad Sci U S A, 2019, 116(24): 11900-11905. DOI: 10.1073/pnas.1901841116..

GUITART X, BONAVENTURA J, REA W, et al . Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease[J ] . Neurobiol Dis, 2016, 96: 47-53. DOI: 10.1016/j.nbd.2016.08.013.

PASQUINI S, CONTRI C, BOREA P A, et al . Adenosine and inflammation: here, there and everywhere[J ] . Int J Mol Sci, 2021, 22(14): 7685. DOI: 10.3390/ijms22147685.

侯明亮, 马琳秋, 李金平, 等. 胰淀素对阿尔茨海默病小鼠脑组织中circRNA和mRNA表达谱的影响[J]. 陆军军医大学学报, 2023, 45(19): 2018-2028. DOI: 10.16016/j.2097-0927.202304089.

HOU M L, MA L Q, LI J P, et al . Effect of amylin on expression profiles of circRNAs and mRNAs in brain tissue of Alzheimer's disease mice[J ] . J Amry Med Univ, 2023, 45(19): 2018-2028.

廖旗荣, 杨红岩, 卢静, 等. 胰淀素对阿尔茨海默病小鼠学习和记忆能力以及Akt信号通路的影响[J]. 陆军军医大学学报, 2024, 46(21): 2467-2474. DOI: 10.16016/j.2097-0927.202404087.

LIAO Q R, YANG H Y, LU J, et al . Effect of amylin on learning and memory abilities and Akt signaling pathway in mice with Alzheimer's disease[J ] . J Amry Med Univ, 2024, 46(21): 2467-2474. DOI:10.16016/j.2097-0927.202404087.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

颈深淋巴-静脉吻合术治疗阿尔茨海默病的病例系列报道

circ-Tns3/miR-671-5p/sirt1轴介导阿尔茨海默病神经元损伤的分子机制

骨钙素在阿尔茨海默病细胞模型中的神经保护作用与机制研究

普兰林肽通过抗氧化应激和PI3K/Akt通路改善阿尔茨海默病小鼠认知功能

卵巢雌激素缺乏经调节海马线粒体功能与胞外基质重塑参与阿尔茨海默病发病与进程